P-346 - Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real...

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anticancer agents
Geriatric Oncology
Colon and Rectal Cancer
Therapy
Biological Therapy
Presenter E. François
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors E. François1, S. Kim2, D. Smith3, G. Deplanque4, S. Gourgou5, F. Rollot-Trad6, S. Gally1, A. Berthier1, L. Mineur7
  • 1Centre Antoine Lacassagne, Nice/FR
  • 2University Hospital of Besancon, Besançon/FR
  • 3University Hospital, Bordeaux/FR
  • 4Saint-Joseph Hospital Group, Paris/FR
  • 5and Data Center for Cancer Clinical Trials, Montpellier/FR
  • 6Curie Institute, Paris/FR
  • 7Sainte-Catherine Institute, Avignon/FR

Abstract

Introduction

Approximately half of the patients with metastatic colorectal cancer (mCRC) are elderly, but very few studies have specifically assessed this population. A prospective real-world study was conducted in France in a cohort of elderly patients (≥75 years-old) with mCRC treated in daily practice with bevacizumab, in order to improve the knowledge on this population and to contribute in optimizing treatment strategy.

Methods

CASSIOPEE is a prospective, multicenter, French non-interventional oncogeriatric study conducted over 24 months. Patients aged 75 years or older with mCRC and treated in first-line with bevacizumab and chemotherapy were eligible. The primary objective is to describe progression-free survival (PFS). Secondary objectives include the description of patients' characteristics, overall survival (OS), bevacizumab regimen, safety and autonomy criteria. Results of a planned interim analysis on patients' characteristics are presented.

Results

Between March 2012 and June 2014, recruitment objective was completed with 404 patients (pts) included: 52% were men, mean age 80.5 (±3.8) with 44% patients aged < 80, 45% aged between 80 and 85, and 11% aged > 85. Localization of the primitive primary tumor was colon (80%), rectum (20%). One metastatic site was found in 64% patients, 2 metastatic sites in 28% and 7% patients had 3 or 4 metastatic sites; the main metastatic sites were liver (65%), including liver only (37%), liver/lung (15%) or liver/peritoneum (6%), lung (33%), including lung only (11%), peritoneum (24%); at diagnosis 54% had stage IV CRC and 23% had stage III. Median time (Q1-Q3) between initial diagnosis and inclusion was 3.0 months (1.0-15.0).

Regarding the modified 4 items Lawton Instrumental Activities of Daily Living Scale (IADL 4 items), about half of the patients (49.5%) had a score of 0, 29.2%, 10.5%, 7.4% and 3.4% had a score of 1, 2, 3 and 4, respectively.

Balducci frailty criteria resulted in 39.2%, 20.6% and 3.8% patients for the type 1, 2, and 3, respectively and was not known for 36.4% of patients.

Main comorbidities were cardiovascular diseases (66%), diabetes (25%) and neuropsychological disorders (13%).

Conclusion

CASSIOPEE is the first non-interventional real-world oncogeriatric study describing the cohort's characteristics of elderly patients with mCRC, whom 56% are 80 years-old or more, treated by first-line bevacizumab combined with chemotherapy in daily practice. Recruitment objective was met. Efficacy, safety data and autonomy criteria will be provided after one and two years of follow-up.